Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil: findings and implications

Gustavo Laine Araujo de Oliveira, Augusto Afonso Guerra Júnior, Brian Godman, Francisco de Assis Acúrcio

Research output: Contribution to journalArticle

3 Citations (Scopus)
53 Downloads (Pure)

Abstract

Introduction: Vildagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4, indicated for the treatment of type 2 diabetes mellitus, combined or not with metformin. This study aims to evaluate the cost-effectiveness of vildagliptin in the Brazilian context. Areas covered: Using MEDLINE, Cochrane Library, Lilacs and CRD, six studies were selected for the economic models. This study utilised cost data in the Brazilian health system to provide the context.
Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a challenge for all health care systems. Although guidelines clearly define first-line treatment, there are several other promising treatments. Vildagliptin is one of them, resulting in a mean lifetime increase of 0.31 years compared to metformin alone and 1.19 more life years compared to other metformin combinations. Considering observational data, life years with dual vildagliptin-containing treatments were 0.37 more compared to other dual treatments. However, its high cost versus generic metformin and its unclear safety profile weakens its subsequent cost-effectiveness. Consequently, the incorporation of vildagliptin or its combination with metformin is currently not recommended for the Brazilian Health Care System. This may change as more data becomes available.
Original languageEnglish
Pages (from-to)109-119
Number of pages11
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume17
Issue number2
Early online date9 Feb 2017
DOIs
Publication statusPublished - 22 Feb 2017

Keywords

  • vildagliptin
  • cost-effectiveness
  • Brazil
  • type 2 diabetes
  • metformin

Cite this